ReviewBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2013
Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas.
Review in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Consensus Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2)-Low Testing in Breast Cancer in Malaysia.Cancers · 2024Guideline
- HER2 in Gastric Cancer: A Comprehensive Analysis Combining Meta-Analysis and DCE-MRI Radiomics.Cancer control : journal of the Moffitt Cancer CenterPooled it
- Analysis ofInternational journal of molecular sciences · 2025Article
- Validation of the Polar Fitness Test for Estimation of Maximal Oxygen Consumption at Rest in Medically Supervised Exercise Training: Comparison with CPET and the 6-Minute Walk Test.Sensors (Basel, Switzerland) · 2025Article
- Diagnosis of hydatidiform moles usingInternational journal of reproductive biomedicine · 2024Article
- The Evaluation ofChildren (Basel, Switzerland) · 2022Article
- Use of Fluorescence In Situ Hybridization (FISH) in Diagnosis and Tailored Therapies in Solid Tumors.Molecules (Basel, Switzerland) · 2020Review
- Article
- The effect of an alternative chromosome 17 probe on fluorescenceExperimental and therapeutic medicine · 2019Article
- ChromogenicOpen access Macedonian journal of medical sciences · 2019Article
- Allocation of Interferon Gamma mRNA Positive Cells in Caecum Hallmarks a Protective Trait Against Histomonosis.Frontiers in immunology · 2018Article
- HER2/Journal of clinical and diagnostic research : JCDR · 2017Article
- Fluorescent in Situ Hybridization and Real-Time Quantitative Polymerase Chain Reaction to EvaluateIranian journal of pathology · 2017Article
- Chromogenic in situ Hybridization Compared with Real time Quantitative Polymerase Chain Reaction to Evaluate HER2/neu Status in Breast Cancer.Iranian journal of pathology · 2017Article
- HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method.Oncology letters · 2016Article
- In situ hybridization to detect and localize signature cytokines of T-helper (Th) 1 and Th2 immune responses in chicken tissues.Veterinary immunology and immunopathology · 2016Article
- Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.International journal of clinical and experimental pathology · 2014Article
- Added value of HER-2 amplification testing by multiplex ligation-dependent probe amplification in invasive breast cancer.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human epidermal growth factor receptor 2 (HER2) has been evaluated in breast cancer patients to identify those most likely to benefit from herceptin-targeted therapy. HER2 amplification, detected in 20-30% of invasive breast tumors, is associated with reduced survival and metastasis. The most frequently used technique for evaluating HER2 protein status as a routine procedure is immunohistochemistry (IHC). HER2 copy number alterations have also been evaluated by fluorescence in situ hybridization (FISH) in moderate immunoexpression (IHC 2+) cases. An alternative procedure to evaluate gene amplification is chromogenic in situ hybridization (CISH), which has some advantages over FISH, including the correlation between HER2 status and morphological features. Other methodologies have also been used, such as silver-enhanced in situ hybridization (SISH) and quantitative real-time RT-PCR, to determine the number of HER2 gene copies and expression, respectively. Here we will present a short and comprehensive review of the current advances concerning HER2 evaluation in human breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.